Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms

• Published in: PloS one Vol. 14; no. 1; p. e0210041
• Main Authors: España, Guido, Hogea, Cosmina, Guignard, Adrienne, Ten Bosch, Quirine A, Morrison, Amy C, Smith, David L, Scott, Thomas W, Schmidt, Alexander, Perkins, T Alex
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 25.01.2019; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Bias; Biology and Life Sciences; Child; Child, Preschool; Clinical trials; Clinical Trials, Phase III as Topic; Computer simulation; Data processing; Dengue; Dengue - drug therapy; Dengue - immunology; Dengue - virology; Dengue fever; Dengue vaccines; Dengue Vaccines - administration & dosage; Dengue Vaccines - immunology; Dengue Virus - drug effects; Dengue Virus - immunology; Dengue Virus - physiology; Disease transmission; Effectiveness; Entomology; Epidemiology; Estimates; Exposure; Heterogeneity; Humans; Immune response; Immune system; Infections; Medicine and Health Sciences; Mosquitoes; Peru; Physiological aspects; Population; Prevention; Public health; Randomized Controlled Trials as Topic; Research and Analysis Methods; Research Design; Treatment Outcome; Vaccine efficacy; Vaccines; Vector-borne diseases; Viral diseases; Viremia; Viremia - drug therapy; Viremia - virology; Viruses; Young Adult; Zika virus; Peru; United States; California; Thailand; United States > US
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0210041

Vaccine efficacy (VE) estimates are crucial for assessing the suitability of dengue vaccine candidates for public health implementation, but efficacy trials are subject to a known bias to estimate VE toward the null if heterogeneous exposure is not accounted for in the analysis of trial data. In light of many well-characterized sources of heterogeneity in dengue virus (DENV) transmission, our goal was to estimate the potential magnitude of this bias in VE estimates for a hypothetical dengue vaccine. To ensure that we realistically modeled heterogeneous exposure, we simulated city-wide DENV transmission and vaccine trial protocols using an agent-based model calibrated with entomological and epidemiological data from long-term field studies in Iquitos, Peru. By simulating a vaccine with a true VE of 0.8 in 1,000 replicate trials each designed to attain 90% power, we found that conventional methods underestimated VE by as much as 21% due to heterogeneous exposure. Accounting for the number of exposures in the vaccine and placebo arms eliminated this bias completely, and the more realistic option of including a frailty term to model exposure as a random effect reduced this bias partially. We also discovered a distinct bias in VE estimates away from the null due to lower detectability of primary DENV infections among seronegative individuals in the vaccinated group. This difference in detectability resulted from our assumption that primary infections in vaccinees who are seronegative at baseline resemble secondary infections, which experience a shorter window of detectable viremia due to a quicker immune response. This resulted in an artefactual finding that VE estimates for the seronegative group were approximately 1% greater than for the seropositive group. Simulation models of vaccine trials that account for these factors can be used to anticipate the extent of bias in field trials and to aid in their interpretation.